ABT-702 [CAS 214697-26-4]

ABT-702 is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC50 of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research[1][2][3].

[214697-26-4]

C22H19BrN6O

463.33

BrC1=CC=CC(C2=C3C(N)=NC=NC3=NC(C4=CC=C(N5CCOCC5)N=C4)=C2)=C1

Adenosine Kinase; Adenosine Receptor

99.61

DMSO : 25 mg/mL (ultrasonic)

-20°C, 3 years (Powder)

Blue Ice

H302, H315, H319, H335

H302, H315, H319, H335